FDA Grants Balixafortide Fast Track Designation for Treatment of Metastatic Breast Cancer Subset

KeepHealthCare.ORG – FDA Grants Balixafortide Fast Track Designation for Treatment of Metastatic Breast Cancer Subset The immunotherapy agent balixafortide (POL6326) has been granted Fast Track designation by the FDA in Continue reading